Please login to the form below

Not currently logged in


This page shows the latest Vumerity news and features for those working in and with pharma, biotech and healthcare.

Biogen pays InnoCare $125m upfront for potential multiple sclerosis treatment

Biogen pays InnoCare $125m upfront for potential multiple sclerosis treatment

Orelabrutinib will fit neatly into Biogen’s MS portfolio, which includes Tecfidera (dimethyl fumarate), Tysabri (natalizumab) and Vumerity (diroximel fumarate).

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Innovative Trials

Innovative Trials specialises in delivering effective global patient recruitment strategies for your clinical trials by adopting a patient and site-centric...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...